Annual EBITDA
-$232.82 M
-$260.58 M-938.64%
December 31, 2023
Summary
- As of February 10, 2025, ACOR annual EBITDA is -$232.82 million, with the most recent change of -$260.58 million (-938.64%) on December 31, 2023.
- During the last 3 years, ACOR annual EBITDA has fallen by -$197.03 million (-550.43%).
Performance
ACOR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly EBITDA
-$12.67 M
+$226.08 M+94.69%
March 31, 2024
Summary
- As of February 10, 2025, ACOR quarterly EBITDA is -$12.67 million, with the most recent change of +$226.08 million (+94.69%) on March 31, 2024.
- Over the past year, ACOR quarterly EBITDA has dropped by -$9.29 million (-274.96%).
Performance
ACOR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
-$241.46 M
-$9.29 M-4.00%
March 31, 2024
Summary
- As of February 10, 2025, ACOR TTM EBITDA is -$241.46 million, with the most recent change of -$9.29 million (-4.00%) on March 31, 2024.
- Over the past year, ACOR TTM EBITDA has dropped by -$274.56 million (-829.60%).
Performance
ACOR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ACOR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -938.6% | -275.0% | -829.6% |
| 3 y3 years | -550.4% | +37.5% | -301.0% |
| 5 y5 years | -535.2% | +65.8% | -10.9% |
ACOR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -938.6% | at low | -133.2% | +1784.9% | -640.0% | at low |
| 5 y | 5-year | -938.6% | at low | -115.8% | +1784.9% | -314.6% | at low |
| alltime | all time | -535.2% | at low | -115.8% | +1867.5% | -314.6% | +42.4% |
Acorda Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | -$12.67 M(-94.7%) | -$241.46 M(+4.0%) |
| Dec 2023 | -$232.82 M(-938.6%) | -$238.75 M(-4355.0%) | -$232.17 M(-619.2%) |
| Sep 2023 | - | $5.61 M(+29.3%) | $44.72 M(+7.4%) |
| Jun 2023 | - | $4.34 M(-228.5%) | $41.64 M(+25.8%) |
| Mar 2023 | - | -$3.38 M(-108.9%) | $33.09 M(+16.9%) |
| Dec 2022 | $27.76 M(-161.6%) | $38.15 M(+1407.7%) | $28.30 M(-318.9%) |
| Sep 2022 | - | $2.53 M(-160.2%) | -$12.93 M(-57.1%) |
| Jun 2022 | - | -$4.20 M(-48.5%) | -$30.15 M(-8.6%) |
| Mar 2022 | - | -$8.17 M(+164.3%) | -$33.00 M(-26.8%) |
| Dec 2021 | -$45.09 M(+26.0%) | -$3.09 M(-79.0%) | -$45.09 M(-59.0%) |
| Sep 2021 | - | -$14.69 M(+108.2%) | -$110.01 M(+60.6%) |
| Jun 2021 | - | -$7.06 M(-65.2%) | -$68.51 M(+13.8%) |
| Mar 2021 | - | -$20.25 M(-70.2%) | -$60.22 M(+68.2%) |
| Dec 2020 | -$35.80 M(-83.6%) | -$68.02 M(-353.6%) | -$35.80 M(-131.8%) |
| Sep 2020 | - | $26.82 M(+2076.6%) | $112.53 M(-168.8%) |
| Jun 2020 | - | $1.23 M(-70.5%) | -$163.49 M(-7.4%) |
| Mar 2020 | - | $4.17 M(-94.8%) | -$176.58 M(-18.9%) |
| Dec 2019 | -$217.80 M(-507.1%) | $80.31 M(-132.2%) | -$217.80 M(-36.7%) |
| Sep 2019 | - | -$249.20 M(+2000.1%) | -$343.94 M(+447.6%) |
| Jun 2019 | - | -$11.87 M(-68.0%) | -$62.80 M(-607.8%) |
| Mar 2019 | - | -$37.05 M(-19.2%) | $12.37 M(-76.9%) |
| Dec 2018 | $53.50 M(-125.5%) | -$45.83 M(-243.5%) | $53.50 M(-147.3%) |
| Sep 2018 | - | $31.94 M(-49.5%) | -$113.05 M(-20.0%) |
| Jun 2018 | - | $63.30 M(+1449.7%) | -$141.38 M(-27.8%) |
| Mar 2018 | - | $4.08 M(-101.9%) | -$195.87 M(-6.7%) |
| Dec 2017 | -$209.46 M(+4936.4%) | -$212.38 M(-5976.6%) | -$209.99 M(-2101.2%) |
| Sep 2017 | - | $3.61 M(-59.0%) | $10.49 M(+47.1%) |
| Jun 2017 | - | $8.81 M(-187.8%) | $7.13 M(-161.5%) |
| Mar 2017 | - | -$10.03 M(-223.9%) | -$11.61 M(+179.0%) |
| Dec 2016 | -$4.16 M(-108.3%) | $8.10 M(+3089.0%) | -$4.16 M(-4.8%) |
| Sep 2016 | - | $254.00 K(-102.6%) | -$4.37 M(-117.6%) |
| Jun 2016 | - | -$9.93 M(+284.1%) | $24.78 M(-44.5%) |
| Mar 2016 | - | -$2.58 M(-132.8%) | $44.63 M(-10.5%) |
| Dec 2015 | $49.85 M(+8.9%) | $7.89 M(-73.2%) | $49.85 M(+7.1%) |
| Sep 2015 | - | $29.41 M(+196.4%) | $46.54 M(+16.4%) |
| Jun 2015 | - | $9.92 M(+276.5%) | $39.97 M(-7.2%) |
| Mar 2015 | - | $2.63 M(-42.4%) | $43.06 M(-5.9%) |
| Dec 2014 | $45.77 M | $4.58 M(-80.0%) | $45.77 M(-19.0%) |
| Sep 2014 | - | $22.84 M(+75.5%) | $56.48 M(+20.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2014 | - | $13.01 M(+143.3%) | $46.89 M(+5.8%) |
| Mar 2014 | - | $5.35 M(-65.0%) | $44.30 M(+16.5%) |
| Dec 2013 | $38.03 M(+23.4%) | $15.29 M(+15.4%) | $38.03 M(+47.2%) |
| Sep 2013 | - | $13.24 M(+27.1%) | $25.83 M(+6.8%) |
| Jun 2013 | - | $10.42 M(-1228.7%) | $24.18 M(+21.0%) |
| Mar 2013 | - | -$923.00 K(-129.9%) | $19.99 M(-35.1%) |
| Dec 2012 | $30.81 M(-23.4%) | $3.09 M(-73.4%) | $30.80 M(-27.1%) |
| Sep 2012 | - | $11.60 M(+86.4%) | $42.28 M(-19.5%) |
| Jun 2012 | - | $6.22 M(-37.1%) | $52.52 M(+8.5%) |
| Mar 2012 | - | $9.90 M(-32.1%) | $48.39 M(+20.3%) |
| Dec 2011 | $40.21 M(-1132.2%) | $14.57 M(-33.3%) | $40.21 M(+29.6%) |
| Sep 2011 | - | $21.83 M(+945.1%) | $31.02 M(+31.4%) |
| Jun 2011 | - | $2.09 M(+21.5%) | $23.60 M(+39.8%) |
| Mar 2011 | - | $1.72 M(-68.0%) | $16.89 M(-533.3%) |
| Dec 2010 | -$3.90 M(-95.0%) | $5.37 M(-62.7%) | -$3.90 M(-87.6%) |
| Sep 2010 | - | $14.42 M(-411.6%) | -$31.30 M(-48.4%) |
| Jun 2010 | - | -$4.63 M(-75.7%) | -$60.65 M(-22.1%) |
| Mar 2010 | - | -$19.06 M(-13.5%) | -$77.86 M(+2.7%) |
| Dec 2009 | -$78.50 M(+7.4%) | -$22.03 M(+47.6%) | -$75.78 M(+1.9%) |
| Sep 2009 | - | -$14.93 M(-31.7%) | -$74.34 M(-5.5%) |
| Jun 2009 | - | -$21.84 M(+28.6%) | -$78.67 M(+8.7%) |
| Mar 2009 | - | -$16.98 M(-17.5%) | -$72.39 M(+1.2%) |
| Dec 2008 | -$73.08 M(+85.3%) | -$20.59 M(+6.9%) | -$71.56 M(+9.2%) |
| Sep 2008 | - | -$19.25 M(+23.7%) | -$65.53 M(+18.6%) |
| Jun 2008 | - | -$15.56 M(-3.6%) | -$55.24 M(+15.8%) |
| Mar 2008 | - | -$16.15 M(+10.9%) | -$47.71 M(+21.2%) |
| Dec 2007 | -$39.45 M(+80.3%) | -$14.56 M(+62.5%) | -$39.36 M(+25.9%) |
| Sep 2007 | - | -$8.96 M(+11.6%) | -$31.26 M(+9.1%) |
| Jun 2007 | - | -$8.03 M(+3.0%) | -$28.64 M(+25.8%) |
| Mar 2007 | - | -$7.80 M(+20.7%) | -$22.77 M(+4.0%) |
| Dec 2006 | -$21.88 M(-32.9%) | -$6.46 M(+1.8%) | -$21.88 M(-8.2%) |
| Sep 2006 | - | -$6.35 M(+194.1%) | -$23.85 M(-3.7%) |
| Jun 2006 | - | -$2.16 M(-68.8%) | -$24.77 M(+9.5%) |
| Mar 2006 | - | -$6.92 M(-17.9%) | -$22.61 M(+44.1%) |
| Dec 2005 | -$32.60 M(-21.8%) | -$8.43 M(+16.0%) | -$15.69 M(+116.0%) |
| Sep 2005 | - | -$7.27 M(-68.8%) | -$7.27 M(-68.8%) |
| Dec 2004 | -$41.70 M(-33.3%) | - | - |
| Dec 2003 | -$62.48 M(+143.0%) | - | - |
| Sep 2003 | - | -$23.27 M | -$23.27 M |
| Jun 2003 | -$25.71 M | - | - |
FAQ
- What is Acorda Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Acorda Therapeutics?
- What is Acorda Therapeutics annual EBITDA year-on-year change?
- What is Acorda Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Acorda Therapeutics?
- What is Acorda Therapeutics quarterly EBITDA year-on-year change?
- What is Acorda Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Acorda Therapeutics?
- What is Acorda Therapeutics TTM EBITDA year-on-year change?
What is Acorda Therapeutics annual EBITDA?
The current annual EBITDA of ACOR is -$232.82 M
What is the all time high annual EBITDA for Acorda Therapeutics?
Acorda Therapeutics all-time high annual EBITDA is $53.50 M
What is Acorda Therapeutics annual EBITDA year-on-year change?
Over the past year, ACOR annual EBITDA has changed by -$260.58 M (-938.64%)
What is Acorda Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ACOR is -$12.67 M
What is the all time high quarterly EBITDA for Acorda Therapeutics?
Acorda Therapeutics all-time high quarterly EBITDA is $80.31 M
What is Acorda Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ACOR quarterly EBITDA has changed by -$9.29 M (-274.96%)
What is Acorda Therapeutics TTM EBITDA?
The current TTM EBITDA of ACOR is -$241.46 M
What is the all time high TTM EBITDA for Acorda Therapeutics?
Acorda Therapeutics all-time high TTM EBITDA is $112.53 M
What is Acorda Therapeutics TTM EBITDA year-on-year change?
Over the past year, ACOR TTM EBITDA has changed by -$274.56 M (-829.60%)